云南白药：2025年上半年省医药公司实现主营业务收入121.64亿元

Core Viewpoint - Yunnan Baiyao reported a solid performance in the first half of 2025, with a focus on diversifying its revenue streams and expanding its non-pharmaceutical business segments [2] Group 1: Financial Performance - The company achieved a main business revenue of 12.164 billion yuan and a net profit of 351 million yuan, reflecting a year-on-year growth of 17.75% [2] - The sales of non-pharmaceutical businesses, including medical devices, cosmetics, and special medical foods, increased by 10.6% year-on-year [2] Group 2: Business Expansion - The new specialty pharmacy business under the outpatient model significantly benefited from the outflow of prescriptions from hospitals, with sales growing by 57% year-on-year [2]